AU2017250025B2 - Bisphenol derivatives and their use as androgen receptor activity modulators - Google Patents

Bisphenol derivatives and their use as androgen receptor activity modulators Download PDF

Info

Publication number
AU2017250025B2
AU2017250025B2 AU2017250025A AU2017250025A AU2017250025B2 AU 2017250025 B2 AU2017250025 B2 AU 2017250025B2 AU 2017250025 A AU2017250025 A AU 2017250025A AU 2017250025 A AU2017250025 A AU 2017250025A AU 2017250025 B2 AU2017250025 B2 AU 2017250025B2
Authority
AU
Australia
Prior art keywords
aco
oac
qac
compound
propan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017250025A
Other languages
English (en)
Other versions
AU2017250025A1 (en
Inventor
Raymond Andersen
Carmen Adriana Banuelos
Kunzhong JIAN
Nasrin R. Mawji
Marianne Dorothy Sadar
Jun Wang
Yu-Chi Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
British Columbia Cancer Agency BCCA
Original Assignee
University of British Columbia
British Columbia Cancer Agency BCCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, British Columbia Cancer Agency BCCA filed Critical University of British Columbia
Publication of AU2017250025A1 publication Critical patent/AU2017250025A1/en
Application granted granted Critical
Publication of AU2017250025B2 publication Critical patent/AU2017250025B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/36—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017250025A 2016-04-15 2017-04-18 Bisphenol derivatives and their use as androgen receptor activity modulators Ceased AU2017250025B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323196P 2016-04-15 2016-04-15
US62/323,196 2016-04-15
PCT/CA2017/000083 WO2017177307A1 (en) 2016-04-15 2017-04-18 Bisphenol derivatives and their use as androgen receptor activity modulators

Publications (2)

Publication Number Publication Date
AU2017250025A1 AU2017250025A1 (en) 2018-11-29
AU2017250025B2 true AU2017250025B2 (en) 2021-06-24

Family

ID=60039402

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017250025A Ceased AU2017250025B2 (en) 2016-04-15 2017-04-18 Bisphenol derivatives and their use as androgen receptor activity modulators

Country Status (14)

Country Link
US (4) US20170298033A1 (enExample)
EP (1) EP3442942B1 (enExample)
JP (2) JP7142577B2 (enExample)
KR (1) KR102409651B1 (enExample)
CN (2) CN109311807B (enExample)
AU (1) AU2017250025B2 (enExample)
BR (1) BR112018071183B1 (enExample)
CA (1) CA3021008A1 (enExample)
ES (1) ES2969445T3 (enExample)
IL (1) IL262338B (enExample)
MX (1) MX392906B (enExample)
NZ (1) NZ748200A (enExample)
RU (1) RU2767257C2 (enExample)
WO (1) WO2017177307A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654811B2 (en) 2015-01-13 2020-05-19 The University Of British Columbia Heterocyclic compounds for cancer imaging and treatment and methods for their use
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2018045450A1 (en) * 2016-09-09 2018-03-15 British Columbia Cancer Agency Branch Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN118684633A (zh) * 2018-10-18 2024-09-24 埃萨制药股份有限公司 雄激素受体调节剂及其使用方法
US20220202780A1 (en) * 2019-03-28 2022-06-30 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020198712A1 (en) * 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN112457366B (zh) * 2019-09-06 2024-03-19 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和应用
KR20230004498A (ko) 2020-04-17 2023-01-06 에싸 파마 아이엔씨. N-말단 도메인 안드로겐 수용체 억제제의 고형분 형태 및 이의 용도
JP7434265B2 (ja) 2020-12-30 2024-02-20 財團法人工業技術研究院 アンドロゲン受容体結合分子およびその使用
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用
KR20220157096A (ko) * 2021-05-20 2022-11-29 연세대학교 산학협력단 암의 예방, 개선 또는 치료용 조성물
KR20220157089A (ko) * 2021-05-20 2022-11-29 연세대학교 산학협력단 암의 예방, 개선 또는 치료용 조성물
WO2023046283A1 (en) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3074974A (en) * 1957-12-06 1963-01-22 Monsanto Chemicals Method for the preparation of diglycidyl ether of tetrachlorobisphenol-a
EP0155238A2 (de) * 1984-03-15 1985-09-18 Ciba-Geigy Ag Verfahren zur Herstellung bestimmter Glycidylverbindungen
WO2012139039A2 (en) * 2011-04-08 2012-10-11 British Columbia Cancer Agency Branch Bisphenol compounds and methods for their use
US20130109758A1 (en) * 2010-01-06 2013-05-02 The University Of British Columbia Bisphenol derivative therapeutics and methods for their use
WO2015031984A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
WO2016112455A1 (en) * 2015-01-13 2016-07-21 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2571217A (en) 1951-10-16 Horace s
US2890189A (en) 1954-06-14 1959-06-09 Johnson & Son Inc S C Alkali soluble resins and compositions containing the same
US3162615A (en) 1961-01-03 1964-12-22 Dow Chemical Co Polyesters from cyclic polyhaloalkane polyols and unsaturated dicarboxylic acids
FR1389005A (fr) 1963-01-09 1965-02-12 Bayer Ag Procédé perfectionné pour durcir des polyépoxydes
SU638596A1 (ru) 1975-09-01 1978-12-25 Государственный Научно-Исследовательский И Проектный Институт Полимерных Клеев Им. Э.Л.Тер-Газаряна Хлоргидриднное производное диаллилизоциануровой кислоты в качестве пластификатора поливинилацетатной эмульсии
US4284574A (en) 1979-06-15 1981-08-18 Ciba-Geigy Corporation Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them
SU929630A1 (ru) * 1980-02-06 1982-05-23 Научно-Исследовательский Институт Биологии При Иркутском Государственном Университете Им.А.А.Жданова Способ получени ди-или триоксидифенил-сульфонов
US4369298A (en) 1980-05-27 1983-01-18 Tokuyama Soda Kabushiki Kaisha Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers
DE3170223D1 (en) 1981-01-13 1985-06-05 Teijin Ltd Ion-permeable composite membrane and its use in selective separation
PL141793B1 (en) 1984-10-08 1987-08-31 Politechnika Warszawska Method of obtaining bisphenolic resins
US5753730A (en) 1986-12-15 1998-05-19 Mitsui Toatsu Chemicals, Inc. Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby
JPH0832844B2 (ja) 1987-02-09 1996-03-29 パイロツトインキ株式会社 筆記板用不透明性インキ
EP0290860B1 (en) 1987-04-27 1995-01-25 Mitsubishi Gas Chemical Company, Inc. Thermosetting resin composition
BR8807088A (pt) 1987-06-01 1989-10-17 Dow Chemical Co Processo para a preparacao de um eter propargilico de um composto hidroxilico aromatico
US5155196A (en) 1987-06-01 1992-10-13 The Dow Chemical Company Polymer resulting from the cure of a preformed chromene-containing mixture
JP2572020B2 (ja) * 1987-06-19 1997-01-16 竹本油脂株式会社 熱硬化性樹脂用難燃剤
DE3821585A1 (de) 1987-09-13 1989-03-23 Hoechst Ag Positiv arbeitendes strahlungsempfindliches gemisch und daraus hergestelltes strahlungsempfindliches aufzeichnungsmaterial fuer hochenergetische strahlung
US4855184A (en) 1988-02-02 1989-08-08 Minnesota Mining And Manufacturing Company Radiation-curable protective coating composition
DE3939760A1 (de) 1989-12-01 1991-06-06 Bayer Ag Verfahren zur lackierung von kunststoffen, lackierte kunststoffe und die verwendung von hierzu geeigneten haftvermittlern
EP0515128A1 (en) 1991-05-23 1992-11-25 Konica Corporation Silver halide color photographic light-sensitive material
JPH0649473A (ja) 1992-08-04 1994-02-22 Asahi Chem Ind Co Ltd 冷媒組成物
DE4323512A1 (de) 1992-09-01 1994-04-28 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
JPH07117349A (ja) 1993-10-27 1995-05-09 Asahi Denka Kogyo Kk 感熱記録材料
MX9703944A (es) 1994-11-29 1998-05-31 Hoechst Marion Roussel Inc Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
DE19526146A1 (de) 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
JPH09176240A (ja) 1995-12-27 1997-07-08 Mitsubishi Chem Corp 光重合性組成物
JPH10133427A (ja) 1996-11-05 1998-05-22 Fuji Xerox Co Ltd 静電潜像現像用キャリア、静電潜像現像剤及び画像形成方法
AR011626A1 (es) 1997-02-07 2000-08-30 Shell Int Research Un procedimiento para la elaboracion de compuestos epoxidos, resinas epoxidas obtenidas mediante dicho procedimiento y un procedimiento para laelaboracion de compuestos intermedios para la elaboracion de compuestos epoxidos
JPH10316803A (ja) 1997-05-16 1998-12-02 Teijin Chem Ltd 難燃性樹脂組成物
IL125840A (en) 1997-08-22 2002-12-01 Teijin Chemicals Ltd Bromine compound production method
JPH11166087A (ja) 1997-12-04 1999-06-22 Teijin Chem Ltd 難燃性樹脂組成物
WO2000001813A2 (en) 1998-06-30 2000-01-13 The University Of British Columbia Peptide inhibitors of androgen-independent activation of androgen receptor
US6245117B1 (en) 1998-08-07 2001-06-12 Ipposha Oil Industries Co., Ltd. Modifier of cellulose fibers and modification method of cellulose fibers
US6218430B1 (en) 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
JP3795679B2 (ja) 1998-09-01 2006-07-12 帝人化成株式会社 臭素化合物の製造方法
US6795776B1 (en) 1999-10-14 2004-09-21 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US6534621B2 (en) 2000-05-18 2003-03-18 Dow Global Technologies Inc. Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom
US6472436B1 (en) 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
AU2001286965A1 (en) 2000-08-31 2002-03-13 Advanced Medicine, Inc. Sodium channel modulators
US6646102B2 (en) 2001-07-05 2003-11-11 Dow Global Technologies Inc. Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7022870B2 (en) 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US7595345B2 (en) 2003-11-20 2009-09-29 Eli Lilly And Company Vitamin D receptor modulators
EP1723161A4 (en) 2004-02-13 2010-04-28 Univ British Columbia RADIOACTIVELY MARKED COMPOUNDS AND COMPOSITIONS, PRECURSORS AND METHOD FOR THE PRODUCTION THEREOF
JP2005325301A (ja) 2004-05-17 2005-11-24 Fuji Photo Film Co Ltd セルロースアシレートドープ組成物、およびセルロースアシレートフィルム
EP1781280A2 (en) 2004-08-18 2007-05-09 Warner-Lambert Company LLC Androgen modulators
JP2006208607A (ja) 2005-01-26 2006-08-10 Fuji Photo Film Co Ltd パターン形成材料、並びにパターン形成装置及び永久パターン形成方法
EA201100689A1 (ru) 2005-03-15 2011-10-31 4Сц Аг N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
JP4753601B2 (ja) 2005-03-23 2011-08-24 旭化成イーマテリアルズ株式会社 感光性組成物
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
EP1792622A1 (en) 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
HUE031972T2 (en) 2005-12-29 2017-08-28 Celtaxsys Inc Diamine derivatives as inhibitors of leukotriene a4 hydrolase
EP4385574A3 (en) 2006-03-27 2024-10-02 The Regents of the University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
JP2007290980A (ja) 2006-04-21 2007-11-08 Shin Etsu Chem Co Ltd 含フッ素（メタ）アクリル酸エステル
DE102006019044A1 (de) 2006-04-25 2007-10-31 Merck Patent Gmbh Antioxidantien
TW200819421A (en) 2006-10-31 2008-05-01 Univ Nat Chunghsing The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste
WO2008101806A2 (en) 2007-02-20 2008-08-28 Basf Se High refractive index monomers, compositions and uses thereof
CN102083780B (zh) 2008-07-02 2017-03-29 不列颠哥伦比亚癌症局分支机构 二缩水甘油醚衍生物治疗剂和它们的使用方法
EP2320907A4 (en) 2008-08-05 2012-09-05 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS
US9388112B2 (en) * 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
KR101819199B1 (ko) 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
WO2012145328A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Dibenzylphenyl compounds and methods for their use
WO2013028572A1 (en) 2011-08-19 2013-02-28 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
JP6226978B2 (ja) 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
SG10201607177XA (en) 2013-05-10 2016-10-28 British Columbia Cancer Agency Ester derivatives of androgen receptor modulators and methods for their use
CN103342892A (zh) 2013-06-06 2013-10-09 西安交通大学 一种双马来酰亚胺树脂的增韧改性剂及其制备方法
US20150010469A1 (en) * 2013-07-03 2015-01-08 British Columbia Cancer Agency Branch Bisphenol ether compounds with novel bridging groups and methods for their use
TW201600499A (zh) 2014-05-15 2016-01-01 巴斯夫歐洲公司 用於製備石墨烯奈米帶的鄰三聯苯
WO2016058082A1 (en) 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
WO2016058080A1 (en) 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch Fluoro-chloro bisphenol ether compounds and methods for their use
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170056336A1 (en) 2015-09-02 2017-03-02 British Columbia Cancer Agency Branch Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2017210771A1 (en) 2016-06-06 2017-12-14 British Columbia Cancer Agency Branch Compounds and compositions for radiation therapy and methods of using the same
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ａｒ＋乳癌の治療方法
WO2018157232A1 (en) 2017-02-28 2018-09-07 British Columbia Cancer Agency Branch Pharmaceutical compositions 'and combinations comprising inhibitors of the androgen receptor a1wd uses thereof
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN118684633A (zh) 2018-10-18 2024-09-24 埃萨制药股份有限公司 雄激素受体调节剂及其使用方法
AU2019395100A1 (en) 2018-12-07 2021-06-03 Sumitomo Pharma Oncology, Inc. Methods for treating castration-resistant and castration- sensitive prostate cancer
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
JP2022521825A (ja) 2019-03-28 2022-04-12 エッサ ファーマ，インコーポレイテッド アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法
US20220202780A1 (en) 2019-03-28 2022-06-30 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
KR20230004498A (ko) 2020-04-17 2023-01-06 에싸 파마 아이엔씨. N-말단 도메인 안드로겐 수용체 억제제의 고형분 형태 및 이의 용도
WO2022060969A1 (en) 2020-09-16 2022-03-24 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3074974A (en) * 1957-12-06 1963-01-22 Monsanto Chemicals Method for the preparation of diglycidyl ether of tetrachlorobisphenol-a
EP0155238A2 (de) * 1984-03-15 1985-09-18 Ciba-Geigy Ag Verfahren zur Herstellung bestimmter Glycidylverbindungen
US20130109758A1 (en) * 2010-01-06 2013-05-02 The University Of British Columbia Bisphenol derivative therapeutics and methods for their use
WO2012139039A2 (en) * 2011-04-08 2012-10-11 British Columbia Cancer Agency Branch Bisphenol compounds and methods for their use
WO2015031984A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
WO2016112455A1 (en) * 2015-01-13 2016-07-21 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use

Also Published As

Publication number Publication date
WO2017177307A1 (en) 2017-10-19
RU2018140071A (ru) 2020-05-19
BR112018071183A2 (pt) 2019-02-12
CN119143585A (zh) 2024-12-17
EP3442942A4 (en) 2019-12-04
KR20190011240A (ko) 2019-02-01
US20250100986A1 (en) 2025-03-27
JP2019513795A (ja) 2019-05-30
EP3442942C0 (en) 2023-11-15
US20170298033A1 (en) 2017-10-19
IL262338B (en) 2022-01-01
JP7142577B2 (ja) 2022-09-27
IL262338A (en) 2018-11-29
ES2969445T3 (es) 2024-05-20
RU2767257C2 (ru) 2022-03-17
CN109311807B (zh) 2024-08-13
KR102409651B1 (ko) 2022-06-16
EP3442942A1 (en) 2019-02-20
US11142508B2 (en) 2021-10-12
NZ748200A (en) 2023-05-26
AU2017250025A1 (en) 2018-11-29
US11919874B2 (en) 2024-03-05
EP3442942B1 (en) 2023-11-15
JP2022120018A (ja) 2022-08-17
CN109311807A (zh) 2019-02-05
RU2018140071A3 (enExample) 2020-06-01
BR112018071183B1 (pt) 2022-06-07
CA3021008A1 (en) 2017-10-19
MX2018012619A (es) 2019-06-24
US20210387957A1 (en) 2021-12-16
US20200317628A1 (en) 2020-10-08
MX392906B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
AU2017250025B2 (en) Bisphenol derivatives and their use as androgen receptor activity modulators
US20220267283A1 (en) Heterocyclic compounds for cancer imaging and treatment and methods for their use
US20210100757A1 (en) Bisphenol ether derivatives and methods for using the same
HK40073885A (en) Heterocyclic compounds for cancer imaging and treatment and methods for their use
HK40073885B (en) Heterocyclic compounds for cancer imaging and treatment and methods for their use
HK40005082B (en) Bisphenol derivatives and their use as androgen receptor activity modulators
HK40005082A (en) Bisphenol derivatives and their use as androgen receptor activity modulators

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ANDERSEN, RAYMOND; SADAR, MARIANNE DOROTHY; JIAN, KUNZHONG; MAWJI, NASRIN R.; WANG, JUN; BANUELOS, CARMEN ADRIANA AND YANG, YU-CHI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired